BTK inhibitors advance treatment for B-cell malignancies

The management of B-cell malignancies, including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), and Waldenström macroglobulinemia (WM), is evolving through the use of targeted Bruton’s tyrosine kinase (BTK) inhibitors.

These therapies work by interrupting the B-cell receptor signaling pathway, which is essential for the development, proliferation, and survival of malignant B cells. Unlike traditional chemotherapy that targets rapidly-dividing cells generally, BTK inhibitors provide a more specific mechanism of action.

Two notable agents are Brukinsa (Zanubrutinib), a covalent inhibitor that forms sustained bonds with the BTK protein, and Jaypirca (Pirtobrutinib). Clinical considerations for these drugs include their distinct binding characteristics, selectivity, safety profiles, and potential utility in previously treated patients.

In the context of value-based oncology, the use of these inhibitors requires clinicians to evaluate more than just efficacy. Decision-making must also incorporate safety, patient quality of life, treatment duration, healthcare utilization, and economic impact.